Chugai and Gero Forge Strategic AI Alliance to Tackle Age-Related Diseases
SHERIDAN, WYOMING – July 08, 2025 – In a landmark agreement that underscores the growing convergence of artificial intelligence and drug discovery, Tokyo-based Chugai Pharmaceutical has entered into a multi-phase research collaboration with Singapore-headquartered biotech Gero to target age-related diseases using AI-driven insights. The deal could exceed $1 billion in total value, positioning both companies at the forefront of longevity-focused pharmaceutical innovation.
AI-Powered Discovery for High-Impact Biologics
Chugai, majority-owned by Roche, will leverage Gero’s proprietary AI target discovery platform to identify novel biological targets linked to aging-related conditions. Based on these targets, Chugai will engineer antibody-based drug candidates using its advanced internal capabilities.